Redcare Pharmacy's Q1 Surge Meets Lingering Investor Skepticism

Redcare Pharmacy's strong Q1 2026 revenue, led by 35% Rx growth, beat estimates. Yet, shares remain down 40% YTD amid unaudited results and leadership changes.

Redcare Pharmacy's preliminary first-quarter figures for 2026 delivered a powerful one-two punch, sending its shares soaring over 12% on the day. Yet, the subsequent 3.8% pullback the very next day underscored a persistent disconnect between the company's operational performance and investor sentiment. The stock remains down roughly 40% since the start of the year, ranking it among the weakest performers in Germany's MDAX index.

The numbers themselves were undeniably strong. Group revenue climbed 18.3% to €848 million, surpassing the analyst consensus of €837 million. Growth was broad-based, but the standout performer was the prescription business. Total Rx revenue surged 35% to €315 million, with the German market alone seeing a 55% jump to €168 million. CEO Olaf Heinrich pointed to the continuously expanded service for e-prescription customers as a key driver for gaining further market share, a claim supported by a rising Net Promoter Score for electronic prescriptions from 73 to 76 points.

After a disappointing prior year, investors also welcomed a decisive reacceleration in Germany's over-the-counter (OTC) segment. Revenue there grew 9.7% to €287 million, a marked improvement from the weak 5.4% growth posted in the final quarter of 2025. The company's active customer base continued to expand, reaching 14.2 million, up from 13.1 million a year earlier and 13.9 million at the end of 2025, showing little sign of material churn despite new competitive entrants.

Management reaffirmed its full-year 2026 guidance, targeting revenue growth of 13-15%, German Rx volume exceeding €670 million, OTC growth between 8-10%, and an adjusted EBITDA margin of at least 2.5%. This year represents the peak of an intensive investment cycle focused on logistics expansion, including a new distribution center in Plze?, Czech Republic, with an annual capacity of 15 million packages.

However, the market's hesitation stems from several open questions. All released figures are preliminary and unaudited, with key details on margins, cash flow, and net income still missing. A complete assessment of profitability must wait for the full report due on May 6, 2026. Furthermore, the company is navigating a significant leadership transition. At the Annual General Meeting on April 15, Hendrik Krampe is set to be formally confirmed as the new Chief Financial Officer, joining from Amazon where he spent eight years as Finance Director for the European Marketplace. This meeting will also seal one of the most extensive board changes in the company's history, with three long-standing supervisory board members departing.

Analyst reaction to the quarter was positive. Jefferies reiterated its Buy rating with a €150 price target, with analyst Martin Comtesse calling the quarter a constructive start to the year. On the competitive front, some recent investor unease was alleviated when Rossmann clarified it does not plan to offer prescription medications online, protecting Redcare's core segment where it holds a commanding 67% market share in Germany.

The coming weeks will be critical. The AGM on April 15 provides the next milestone, testing whether the leadership overhaul can proceed smoothly. For the stock to sustain its recent rebound, the company must prove in May that the OTC recovery is durable and that its heavy investments are paving the way for improved profitability.